Safety consideration in the development of anti-tumor monoclonal antibodies during drug development

Articles

ORIGINAL RESEARCH

Published on 21 Aug 2024

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database

ORIGINAL RESEARCH

Published on 08 Aug 2024

In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics

ORIGINAL RESEARCH

Published on 23 Jul 2024

A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study

ORIGINAL RESEARCH

Published on 25 Jun 2024

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

REVIEW

Published on 30 Apr 2024

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

ORIGINAL RESEARCH

Published on 05 May 2023

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

Share on

Frontiers in Oncology

Submit your idea

Articles

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database

In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics

A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

Frontiers in Oncology